glutamic acid has been researched along with Parkinson Disease in 232 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (3.88) | 18.7374 |
| 1990's | 45 (19.40) | 18.2507 |
| 2000's | 74 (31.90) | 29.6817 |
| 2010's | 74 (31.90) | 24.3611 |
| 2020's | 30 (12.93) | 2.80 |
| Authors | Studies |
|---|---|
| Kadgien, CA; Kamesh, A; Milnerwood, AJ | 1 |
| Boutin, J; Fougère, M; Neszvecsko, K; Ryczko, D; Sarret, P; van der Zouwen, CI | 1 |
| Chen, J; Dong, LG; He, KJ; Hu, H; Li, D; Liu, CF; Mao, CJ; Ren, C; Wang, F; Zhang, JB | 1 |
| Bhatte, SH; Buck, SA; Erickson-Oberg, MQ; Freyberg, Z; McKellar, CD; Ramanathan, VP; Rubin, SA | 1 |
| Chu, CT; Lizama, BN; Verma, M | 1 |
| Frouni, I; Huot, P | 1 |
| Boumezbeur, F; Chassain, C; Cladiere, A; Debilly, B; Durif, F; Marques, AR; Pereira, B; Thobois, S; Tsoutsos, C | 1 |
| Jia, J; Li, M; Su, W; Wang, K; Wang, X | 1 |
| Dahlmanns, JK; Dahlmanns, M; Savaskan, N; Steiner, HH; Yakubov, E | 1 |
| Doppler, CEJ; Farrher, E; Fink, GR; Kalbe, E; Ophey, A; Pagel, N; Seger, A; Shah, NJ; Sommerauer, M | 1 |
| Chang, CH; Cheng, KC; Chok, D; Ho, CT; Koh, YC; Nagabhushanam, K; Pan, MH; Wei, CC; Wu, CT | 1 |
| Chernov, MM; Leiter, JC; Swan, CB | 1 |
| Awasthi, A; Kumar, S; Raj, K; Singh, S | 1 |
| Banerjee, R; Datta, I; Holla, V; Kamble, N; Kumar Pal, P; Potdar, C; Raj, A; Yadav, R | 1 |
| Arunachalam, S; Ayoob, K; Azimullah, S; Beiram, R; Meeran, MFN; Ojha, S | 1 |
| D'Silva, T; Denne, T; Hiller, A; Meshul, CK; Moore, C; Shinto, L; Soumyanath, A; Whitner, C; Winfrey, LC | 1 |
| Fu, J; Gao, X; Liu, S; Lu, F; Lu, Y; Mohammed, SAD; Nan, Y; Wang, T; Wang, Y | 1 |
| Liu, M; Tuo, J; Xu, Z; Yu, C; Zhang, F; Zhang, J; Zhang, L | 1 |
| Chaurasia, RN; Dash, D; Gautam, D; Naik, MU; Naik, UP; Yadav, SK | 1 |
| Fu, P; Ko, JK; Lin, K; Yung, KK; Zhang, S; Zhang, Z | 1 |
| Chen, C; Dai, Y; Ding, L; Li, H; Lu, Z; Mo, M; Wei, L; Wu, H; Xu, P; Zou, J | 1 |
| Bonizzoni, E; Cattaneo, C; Jost, WH | 1 |
| Ahn, H; Choi, JY; Han, SJ; Jung, KH; Kang, KJ; Lee, KC; Lee, YJ; Nam, KR; Oh, SJ; Park, JA | 1 |
| Aro, P; Bercow, M; Khrisat, T; Li, N; Liu, Z; Matsumoto, J; Peskind, E; Quinn, JF; Sheng, L; Shi, M; Soltys, D; Stewart, T; Thorland, E; Tian, C; Xie, Z; Yang, D; Zabetian, CP; Zhang, J | 1 |
| Aiello, C; Bonanni, L; Bubbico, G; Calvanese, F; Delli Pizzi, S; Edden, RAE; Esposito, R; Ferretti, A; Franciotti, R; Onofrj, M; Sensi, SL; Tartaro, A; Zöllner, HJ | 1 |
| Civiero, L; Iovino, L; Tremblay, ME | 1 |
| Furlong, TM; Gibson, AS; Keefe, KA | 1 |
| Creed, RB; Farmer, CB; Goldberg, MS; McMahon, LL; Roberts, RC | 1 |
| D'Acunto, CW; Gonzalez, G; Grúz, J; Kaňovský, P; Strnad, M | 1 |
| Cragg, SJ; Zhang, YF | 1 |
| Ibrahim, FM; Imran, M; Jugreet, S; Keenoo, BS; Lobine, D; Mahomoodally, MF; Sadeer, N; Suroowan, S; Venugopala, KN; Zengin, G | 1 |
| Han, J; Shen, Y; Su, LD; Wang, N | 1 |
| Pelosi, A | 1 |
| Atieh, TB; Baum, J; Janowska, MK; Khare, SD; Moriarty, GM; Olson, MP | 1 |
| Cheng, Y; Liu, QS; Ma, J; Pan, RY; Qin, XY; Wu, HT | 1 |
| Bjorklund, G; Chirumbolo, S; Dadar, M; Mutter, J; Stejskal, V; Urbina, MA | 1 |
| Farino, ZJ; Freyberg, RJ; Freyberg, Z; Hnasko, TS; Lu, W; Przedborski, S; Sonders, MS; Steinkellner, T; Villeneuve, M; Zell, V | 1 |
| Ancona, E; Barassi, G; Bellomo, RG; Bonanni, L; Carmignano, SM; Delli Pizzi, S; Franciotti, R; Onofrj, M; Saggini, R; Supplizi, M | 1 |
| Bagga, P; Borthakur, A; Crescenzi, R; D'Aquilla, K; Detre, JA; Greenberg, J; Hariharan, H; Martinez, D; Pickup, S; Reddy, R; Singh, A; Verma, G | 1 |
| Baumann, CR; Baumann-Vogel, H; O'Gorman Tuura, RL | 1 |
| Jamwal, S; Kumar, P | 1 |
| Balbona, JT; Blakely, RD; Gibson, CL; Hall, DH; Nguyen, KCQ; Niedzwiecki, A; Rodriguez, P | 1 |
| Morioka, H; Nishio, R; Takeda, A; Takeuchi, A; Tamano, H | 1 |
| Du, Y; Kondapalli, J; Surmeier, DJ; Tanimura, A; Wokosin, DL | 1 |
| Chakravarthy, VS; Mandali, A; Muddapu, VR; Ramaswamy, S | 1 |
| Hou, L; Lin, X; Liu, X; Qiao, D; Shi, K | 1 |
| Casey, B; Creed, RB; Dave, KD; Goldberg, MS; Janssens, HB; Menalled, L; Rassoulpour, A; van der Hart, M; Veinbergs, I | 1 |
| Furuhata, R; Komata, Y; Morioka, H; Nishio, R; Takeda, A; Tamano, H | 1 |
| Antony, J; Choephel, T; Jeyarani, V; Jose, A; Kannan, E; Karolina Sahadevan, S; Manisha, C; Mannan Thodukayil, N; Thomas, P | 1 |
| Bhattacharya, P; Borah, A; Deb, S; Dutta, A; Justin Thenmozhi, A; Manivasagam, T; Paul, R; Phukan, BC | 1 |
| Conn, PJ; Moehle, MS | 1 |
| Bonsi, P; Imbriani, P; Madeo, G; Martella, G; Meringolo, M; Pisani, A; Ponterio, G; Tassone, A | 1 |
| Alonso-Gil, S; Conde, S; Gil, C; Martínez, A; Morales-García, JA; Palomo, V; Pérez, C; Pérez, DI; Pérez-Castillo, A; Santos, A; Susín, C | 1 |
| Cabrera, R; Casas, S; Cremaschi, F; Giuliani, F; Yunes, R | 1 |
| Morales, I; Rodriguez, M; Sabate, M | 1 |
| Majláth, Z; Obál, I; Toldi, J; Vécsei, L | 1 |
| Ambrosi, G; Blandini, F; Cerri, S | 1 |
| Jeon, BS; Kim, YE | 1 |
| Majláth, Z; Vécsei, L | 1 |
| Baufreton, J; Bioulac, BH; Dupuis, JP | 1 |
| Halemani, ND | 1 |
| Amalric, M | 1 |
| Cook, TJ; Dreisbach, MT; Hoekstra, JG; Hoffer, ZS; Mattison, H; Stewart, T; Zhang, J | 1 |
| Buchanan, RJ; Darrow, D; Gjini, K; Nadasdy, Z; Robinson, JL; Varga, G | 1 |
| Cintra, AC; Martins, NM; Sampaio, SV; Santos, AC; Santos, NA; Sartim, MA | 1 |
| Aschner, M; Bowman, AB; Kwakye, GF; Mukhopadhyay, S; Paoliello, MM | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Barajas, A; Chen, A; Krantz, DE; Martin, CA; Martin, NT; Myers, KM; Schweizer, FE | 1 |
| Chassain, C; Couraud, S; Durif, F; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Salin, P; Vitale, F | 1 |
| Liu, F; Ma, B; Wang, SJ; Wang, YC; Wang, ZM; Yu, PH | 1 |
| Qu, S; Tan, F; Xu, P; Zhang, Y | 1 |
| Filiz, Z; Korkmaz, OT; Kuş, G; Şener, E; Tunçel, N; Ulupinar, E; Yelkenli, İH | 1 |
| Blobaum, AL; Bubser, M; Conn, PJ; Daniels, JS; Engers, DW; Hopkins, CR; Javitch, JA; Jones, CK; Lin, X; Lindsley, CW; Loch, MT; Niswender, CM; Rodriguez, AL; Thompson Gray, A | 1 |
| Linseman, DA; Taram, F; Winter, AN | 1 |
| Bimpisidis, Z; Dumas, S; Konradsson-Geuken, Å; Lagerström, MC; Smith-Anttila, CJ; Viereckel, T; Vlcek, B; Wallén-Mackenzie, Å | 1 |
| Augustine, EC; Awatramani, R; Chan, CS; Cui, Q; Fan, IB; Fiske, MP; Kennedy, RT; Mabrouk, OS; Pamukcu, A; Pitt, JE; Poulin, JF; Young, KA | 1 |
| Kim, KT; Kim, SH; Kim, W; Song, H | 1 |
| Cilluffo, M; Fernandez, C; Koo, BK; Littlejohn, K; Sarafian, TA; Watson, JB; Whitelegge, JP; Yuan, S | 1 |
| He, X; Meng, X; Qu, S; Tong, H; Wu, X; Zhang, X; Zhang, Y | 1 |
| Kitta, T; Matsumoto, M; Mitsui, T; Nonomura, K; Tanaka, H; Yoshioka, M | 1 |
| Hasim, S; Lakshminarasimhan, M; Pozharski, E; Remington, BC; Wilson, MA; Witt, AC | 1 |
| Obeso, JA; Schapira, AH | 1 |
| Sengpiel, F; Vorobyov, V | 1 |
| Ionov, ID | 1 |
| Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE | 1 |
| den Hollander, JA; Griffith, HR; Marson, DC; O'Brien, T; Okonkwo, OC; Watts, RL | 1 |
| Ehlers, MD; Helton, TD; Lee, MC; Mu, Y; Otsuka, T | 1 |
| Mattson, MP | 1 |
| Ahmad, R; Blackinton, J; Cookson, MR; Greggio, E; Lakshminarasimhan, M; Raza, AS; Thomas, KJ; Wilson, MA | 1 |
| Koch, RJ; Meshul, CK; Moore, C; Sweeney, JE; Walker, RH | 1 |
| Emre, M | 1 |
| Aarsland, D; Alves, G; Ballard, C; Bostrom, F; Kossakowski, K; Leroi, I; Londos, E; Minthon, L; Pozo-Rodriguez, F; Walker, Z | 1 |
| Caudle, WM; Zhang, J | 1 |
| Liu, Y; Schubert, DR | 1 |
| Bax, A; Bodner, CR; Dobson, CM; Maltsev, AS | 1 |
| Camacho, EM; Chen, CX; Fon, EA; Gehring, K; Grenier, K; Kozlov, G; McPherson, PS; Trempe, JF | 1 |
| Raju, DV; Smith, Y; Villalba, RM | 1 |
| Surmeier, DJ | 1 |
| Bjorklund, T; Kordower, JH | 1 |
| Dal Bo, G; Fasano, C; Kortleven, C; Thibault, D; Trudeau, LE | 1 |
| Austin, PJ; Betts, MJ; Broadstock, M; Duty, S; Mitchell, SN; O'Neill, MJ | 1 |
| Calabresi, P; Di Filippo, M | 1 |
| Gao, DM; Kang, N; Liu, H; Zhang, XL; Zhao, L | 1 |
| Artal, J; Fayed, N; Modrego, PJ; Olmos, S | 1 |
| Fernández-Ruiz, J; García, C; García-Arencibia, M; Palomo-Garo, C; Pertwee, R; Ramos, J | 1 |
| Austin, PJ; Betts, MJ; Broadstock, M; Duty, S | 1 |
| Deng, C; Huang, XF; Wang, Q; Wu, A; Xiong, Z; Xu, Y; Yan, J; Yang, Y; Yang, YG; Yenari, MA; Ying, W; Zhang, L; Zhu, C | 1 |
| Bincoletto, C; Carvalho, JT; Hirata, H; Lopes, GS; Oseki, KT; Rocha, KK; Rodrigues, L; Smaili, SS; Ureshino, RP | 1 |
| Cenci, MA; Sgambato-Faure, V | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Feng, Z; Gorelenkova, O; Yang, J; Zheng, M | 1 |
| Gharibzadeh, S; Sarbaz, Y; Towhidkhah, F | 1 |
| Girault, JA | 1 |
| Jia, J; Sun, ZL; Yu, F | 1 |
| Alexander, R; Kanes, S; Lee, CM; McCarthy, DJ; Pathak, S; Sanacora, G; Smith, MA | 1 |
| Deng, J; Gong, X; Jia, J; Jia, Y; Sun, Z; Wang, X | 1 |
| Bai, GH; Gao, HC; Li, XK; Lin, L; Song, CY; Xiang, Y; Yan, ZH; Ye, FQ; Zhu, H | 1 |
| Gluck, MA; Herzallah, MM; Moustafa, AA | 1 |
| Abrusán, G | 1 |
| Fülöp, F; Klivényi, P; Szalárdy, L; Toldi, J; Vécsei, L; Zádori, D | 1 |
| Górska, A; Gołembiowska, K; Kamińska, K; Noworyta-Sokołowska, K; Wardas, J | 1 |
| Aschner, M; Sidoryk-Wegrzynowicz, M | 1 |
| Chase, TN; Oh, JD | 1 |
| Gołembiowska, K; Konieczny, J; Ossowska, K; Wolfarth, S | 1 |
| Brekke, L; Ebadi, M; Sangchot, P; Sharma, S; Shavali, S | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV | 1 |
| Abercrombie, ED; Cobb, WS | 1 |
| Bianchi, L; Bolam, JP; Della Corte, L; Galeffi, F | 1 |
| Damier, P; Drapier, S | 1 |
| Barcikowska, M; Barczak, A; Chodakowska-Zebrowska, M; Czyzewski, K; Gabryelewicz, T; Kijanowska-Haładyna, B; Kotapka-Minc, S; Kuźnicki, J; Pepłońska, B; Pfeffer, A; Przekop, I; Religa, D; Styczyńska, M; Szybińska, A; Wasiak, B; Zekanowski, C; Łuczywek, E | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| Ding, JH; Gu, B; He, HR; Hu, G; Meng, CH; Yang, YL | 1 |
| Kunz, WS; Wallesch, CW; Wiedemann, FR; Winkler-Stuck, K | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Picconi, B; Rossi, S | 1 |
| Arnold, G; Bonuccelli, U; Cattaneo, C; Fariello, RG; Kwiecinski, H; Onofrj, M; Sala, P; Stocchi, F; Szczudlik, A; Thomas, A; Van Dijk, A | 1 |
| Guillet, B; Kerkerian-Le Goff, L; Melon, C; Robelet, S; Salin, P | 1 |
| Duan, CL; Ji, M; Sun, XH; Yang, H | 1 |
| Barlow, BK; Brooks, AI; Cory-Slechta, DA; Richfield, EK; Thiruchelvam, M | 1 |
| Mignon, LJ; Wolf, WA | 1 |
| Baunez, C; Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Picconi, B; Pisani, A; Rossi, S | 1 |
| Kress, GJ; Reynolds, IJ | 1 |
| Ding, JH; Hu, G; Hu, LF; Liu, SY; Shi, XR; Sun, YH; Wang, S; Yao, HH | 1 |
| Chan, YS; Chen, LW; Yung, KL | 1 |
| Aia, P; Gruetter, R; Lowary, J; Oz, G; Terpstra, M; Tkác, I; Tuite, PJ | 1 |
| de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C | 1 |
| Fernández-Ruiz, J; Gonzáles, S | 1 |
| Johnson, SW; Shen, KZ | 1 |
| Aksu, M; Bara-Jimenez, W; Chase, TN; Dimitrova, TD; Sherzai, A | 1 |
| Chen, JF; Kalda, A; Oztas, E; Yu, L | 1 |
| Di Luca, M; Gardoni, F | 1 |
| Atherton, JF; Baufreton, J; Bevan, MD | 1 |
| Akaike, A; Izumi, Y; Katsuki, H; Kume, T; Sawada, H; Shimohama, S; Yamamoto, N | 1 |
| Dopico, JG; Gonzalez-Hernandez, T; Morales, I; Rodriguez, M; Sabate, M | 1 |
| Ariani, F; Cambi, F; Ciacci, G; Malandrini, A; Mari, F; Mencarelli, MA; Renieri, A; Rossi, S; Squillaro, T; Ulivelli, M | 1 |
| Ossowska, K; Pilc, A | 1 |
| Mignon, L; Wolf, WA | 1 |
| Danish, SF; Moyer, JT | 1 |
| Aasly, JO; Farrer, MJ; Haugarvoll, K; Ross, OA; Toft, M; White, LR | 1 |
| Durif, F; Fraix, V; Kickler, N; Krack, P; Krainik, A; Lamalle, L; Lebas, JF; Pollak, P; Rémy, C; Segebarth, C | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Marti, M; Mela, F; Morari, M | 1 |
| Griffith, HR; Hollander, JA; O'Brien, T; Okonkwo, OC | 1 |
| Francis, PT; Perry, EK | 1 |
| Banerjee, R; Ciborowski, P; Garg, SK; Gendelman, HE; Glanzer, JG; Kadiu, I; Nordgren, T; Reynolds, AD | 1 |
| McLennan, H | 1 |
| Berl, S; Plaitakis, A | 1 |
| Yoshida, M | 1 |
| Mizuno, Y; Tanaka, Y | 1 |
| Kawakami, H; Nakamura, S; Tanaka, K; Yamashita, H; Zhang, YX | 1 |
| Klockgether, T; Turski, L | 2 |
| Starr, MS | 1 |
| Greenberg, DA | 1 |
| Gerlach, M; Riederer, P; Youdim, MB | 1 |
| Brunner, LC; Cotman, CW; Joyce, JN; Marshall, JF; Ułas, J; Weihmuller, FB | 1 |
| Meldrum, BS | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Lange, KW; Riederer, P; Youdim, MB | 1 |
| Andrén, PE; Gunne, LM | 1 |
| Baas, H; Fischer, PA; Zipp, F | 1 |
| Greenamyre, JT | 1 |
| Chase, TN; Engber, TM; Mouradian, MM | 1 |
| Blandini, F; Greenamyre, JT; Porter, RH | 1 |
| Akaike, A; Kawamura, T; Kimura, J; Sawada, H; Shimohama, S; Tamura, Y | 1 |
| Arenas, J; Benito-León, J; Cisneros, E; Gasalla, T; Gómez, P; Jiménez-Jiménez, FJ; Molina, JA; Navarro, JA; Ortí-Pareja, M; Vargas, C | 1 |
| Clarke, CE; Horsman, A; Lowry, M | 1 |
| Ho, DY; Sapolsky, RM | 1 |
| Kornhuber, J; Lange, KW; Riederer, P | 1 |
| Bezard, E; Bioulac, B; Boraud, T; Gross, CE | 1 |
| Aston-Jones, G; Gerfen, CR; Grace, AA | 1 |
| Mally, J; Stone, TW; Szalai, G | 1 |
| Blandini, F; Greenamyre, JT | 1 |
| Kötter, R; Wickens, J | 1 |
| Akaike, A; Ibi, M; Kihara, T; Sawada, H; Shimohama, S; Urushitani, M | 1 |
| Schmidt, WJ | 2 |
| Albers, DS; Sonsalla, PK; Zeevalk, GD | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L | 1 |
| Albers, DS; Iadarola, MJ; Standaert, DG; Weiss, SW | 1 |
| Herrera-Marschitz, M; Hökfelt, T; Koistinaho, J; Rodríguez-Puertas, R | 1 |
| Bhattacharya, S; Brooks, DJ; Bryant, DJ; Cox, IJ; Sargentoni, J; Seery, JP; Taylor-Robinson, SD; Turjanski, N | 1 |
| Rascol, O | 1 |
| Cheng, FC; Dryhurst, G; Han, J; Yang, Z | 1 |
| Awad, H; Bradley, SR; Conn, PJ; Levey, AI; Marino, MJ; Rouse, ST; Wittmann, M | 1 |
| Bergmans, PL; Kuiper, MA; Scheltens, P; Teerlink, T; Visser, JJ; Wolters, EC | 1 |
| Begni, B; Bianchi, G; Ferrarese, C; Frattola, L; Frigo, M; Pecora, N; Piolti, R; Riva, R; Sala, G; Zoia, C | 1 |
| Brotchie, J; Ravenscroft, P | 1 |
| Casper, D; Rempel, N; Werner, P; Yaparpalvi, U | 1 |
| Greenamyre, JT; MacKenzie, G; Peng, TI; Stephans, SE | 1 |
| Plaitakis, A; Shashidharan, P | 1 |
| Bernardi, G; Calabresi, P; Centonze, D | 1 |
| Clarke, CE; Lowry, M | 1 |
| Baas, H | 1 |
| Huganir, RL; Lee, HK; Ong, WY; Wang, XS | 1 |
| Hornykiewicz, O | 1 |
| Albizzati, MG; Begni, B; Brighina, L; Crosti, F; Dalprà, L; Ferrarese, C; Frattola, L; Piolti, R; Ricci, G; Rigoldi, M; Sala, G; Tremolizzo, L | 1 |
| Barstow, KL; Falkenburger, BH; Mintz, IM | 1 |
| Berke, JD; Hyman, SE; Krause, M; Lavoie, B; Sgambato, V; Vincent, M; Zhu, PP | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Sherki, Y; Ziv, I | 1 |
| Difazio, MC; Hollingsworth, Z; Penney, JB; Young, AB | 1 |
| Beal, MF | 1 |
| Danielczyk, W; Kornhuber, J; Lange, KW; Riederer, P | 1 |
| Canevari, L; Dagani, F; Di Paolo, E; Ferrari, R; Tosca, P; Verzé, S; Zerbi, F | 1 |
| Ikeda, K; Iwasaki, Y; Kinoshita, M; Shiojima, T | 1 |
| Bjurling, P; Hartvig, P; Imamura, K; Koshimura, K; Långström, B; Mataga, N; Miwa, S; Onoe, H; Tedroff, J; Watanabe, Y | 1 |
| Carlsson, A; Carlsson, M | 1 |
| Mizuno, Y; Suzuki, K; Yoshida, M | 1 |
| Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM | 1 |
| Meldrum, B | 1 |
| Barkhatova, VP | 1 |
| Chang, LJ; Gilbert, J; Hornykiewicz, O; Kish, SJ; Rajput, A; Rozdilsky, B; Shannak, K | 1 |
| Amsler, U; Cuénod, M; Perschak, H; Siegfried, J; Vischer, A | 1 |
71 review(s) available for glutamic acid and Parkinson Disease
| Article | Year |
|---|---|
Roles of VGLUT2 and Dopamine/Glutamate Co-Transmission in Selective Vulnerability to Dopamine Neurodegeneration.
Topics: Dopamine; Dopaminergic Neurons; Glutamic Acid; Humans; Parkinson Disease; Vesicular Glutamate Transport Protein 2 | 2022 |
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration.
Topics: Animals; Glutamic Acid; Mammals; Mitochondria; Neurodegenerative Diseases; Neurons; Parkinson Disease | 2022 |
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; N-Methylaspartate; Parkinson Disease | 2022 |
Glial Glutamate Transporter-Mediated Plasticity: System x
Topics: Alzheimer Disease; Amino Acid Transport System X-AG; Amino Acid Transport System y+; Amyotrophic Lateral Sclerosis; Antioxidants; Cystine; Glioma; Glutamic Acid; Humans; Microglia; Multiple Sclerosis; Parkinson Disease | 2023 |
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
Topics: Aged; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Middle Aged; N-Methylaspartate; Neuroinflammatory Diseases; Parkinson Disease; Quality of Life; Receptors, N-Methyl-D-Aspartate | 2023 |
Glutamate Receptor Dysregulation and Platelet Glutamate Dynamics in Alzheimer's and Parkinson's Diseases: Insights into Current Medications.
Topics: Alzheimer Disease; Animals; Glutamic Acid; Humans; Parkinson Disease; Receptors, Glutamate | 2023 |
Roles of Glutamate Receptors in Parkinson's Disease.
Topics: Animals; Clinical Trials as Topic; Drug Discovery; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glutamic Acid; Humans; Molecular Targeted Therapy; Neurotransmitter Agents; Parkinson Disease; Receptors, Glutamate; Signal Transduction; Substantia Nigra; Synaptic Transmission; Treatment Outcome | 2019 |
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells.
Topics: Amino Acid Transport System X-AG; Glutamic Acid; Homeostasis; Humans; Inflammation; Neuroglia; Neurotransmitter Agents; Parkinson Disease; Receptors, Glutamate | 2020 |
Potential of Medicinal Plants as Neuroprotective and Therapeutic Properties Against Amyloid-β-Related Toxicity, and Glutamate-Induced Excitotoxicity in Human Neural Cells.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Glutamic Acid; Humans; Parkinson Disease; Plants, Medicinal | 2021 |
Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective.
Topics: Alzheimer Disease; Autism Spectrum Disorder; Glutamic Acid; Humans; Mental Disorders; Parkinson Disease | 2022 |
Cell-specific α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Glutamic Acid; Humans; Parkinson Disease | 2017 |
Metals and Parkinson's Disease: Mechanisms and Biochemical Processes.
Topics: alpha-Synuclein; Amyloidogenic Proteins; Chelation Therapy; Dopaminergic Neurons; Drug Synergism; Glutamic Acid; Glutathione; Glutathione Peroxidase; Humans; Metals, Heavy; Oxidative Stress; Parkinson Disease; Selenoproteins | 2018 |
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
Topics: Acetylcholine; Adenosine; Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Huntington Disease; Neuropeptides; Parkinson Disease; Synaptic Transmission | 2019 |
Neuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson's disease therapeutics.
Topics: Animals; Brain; Glutamates; Glutamic Acid; Humans; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Tea | 2019 |
Roles of the M
Topics: Acetylcholine; Basal Ganglia; Cholinergic Neurons; Dopamine; Dystonia; Glutamic Acid; Humans; Interneurons; Molecular Targeted Therapy; Movement Disorders; Muscarinic Antagonists; Neostriatum; Parkinson Disease; Receptor, Muscarinic M4; Receptors, Dopamine; Synaptic Transmission | 2019 |
Mental disturbances in Parkinson's disease and related disorders: the role of excitotoxins.
Topics: Dopamine; Glutamic Acid; Humans; Kynurenine; Mental Disorders; Neuroprotective Agents; Neurotoxins; Parkinson Disease | 2014 |
A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.
Topics: Animals; Cell Death; Glutamic Acid; Humans; Neurons; Parkinson Disease; Synapses | 2014 |
Genetic susceptibility of impulse control and related behavior in Parkinson's disease.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Female; Genetic Predisposition to Disease; Glutamic Acid; Humans; Male; Parkinson Disease; Receptors, Dopamine; Receptors, Serotonin; Serotonin | 2014 |
Long-term depression at distinct glutamatergic synapses in the basal ganglia.
Topics: Animals; Basal Ganglia; Dopamine; Glutamic Acid; Humans; Long-Term Synaptic Depression; Neuronal Plasticity; Parkinson Disease; Synapses | 2014 |
Does limiting glutamatergic transmission in subthalamic nucleus mimic deep brain stimulation?
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Glutamic Acid; Humans; Parkinson Disease; Subthalamic Nucleus | 2014 |
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Metabotropic Glutamate | 2015 |
Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnesium; Manganese Poisoning; Parkinson Disease; Parkinsonian Disorders | 2015 |
Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's Disease.
Topics: Animals; Brain; Glutamate Plasma Membrane Transport Proteins; Glutamic Acid; Humans; Neurons; Parkinson Disease; Synapses; Synaptic Transmission | 2016 |
Self-amplification of nigral degeneration in Parkinson's disease: a hypothesis.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Cerebrovascular Circulation; Glutamic Acid; Histamine; Humans; Locus Coeruleus; Neuropeptides; Parkinson Disease; Substantia Nigra | 2008 |
Glutamate and neurotrophic factors in neuronal plasticity and disease.
Topics: Alzheimer Disease; Animals; Brain Diseases; Brain-Derived Neurotrophic Factor; Glutamic Acid; Humans; Nerve Growth Factors; Neurites; Neurogenesis; Neuronal Plasticity; Neurons; Parkinson Disease; Receptors, Glutamate; Receptors, Nerve Growth Factor; Signal Transduction; Stroke | 2008 |
Glutamate, excitotoxicity, and programmed cell death in Parkinson disease.
Topics: Animals; Autophagy; Excitatory Amino Acids; Glutamic Acid; Humans; Neurotransmitter Agents; Parkinson Disease; Polymorphism, Single Nucleotide; Signal Transduction | 2009 |
Gene therapy for Parkinson's disease.
Topics: Animals; Clinical Trials, Phase II as Topic; Dopamine; Enzyme Therapy; Enzymes; Genetic Therapy; Glutamic Acid; Humans; Intercellular Signaling Peptides and Proteins; Parkinson Disease | 2010 |
[Recent discoveries on the function and plasticity of central dopamine pathways].
Topics: Animals; Brain; Dopamine; Glutamic Acid; Humans; Models, Neurological; Nerve Tissue Proteins; Neural Pathways; Neuronal Plasticity; Neurons; Parkinson Disease; Receptors, Dopamine; Schizophrenia; Signal Transduction; Substantia Nigra; Synaptic Transmission; Ventral Tegmental Area | 2010 |
The role of mitochondrial function in glutamate-dependent metabolism in neuronal cells.
Topics: Alzheimer Disease; Animals; Autophagy; Calcium Signaling; Energy Metabolism; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Huntington Disease; Mitochondria; Neuroglia; Neuronal Plasticity; Neurons; Neurotoxicity Syndromes; Parkinson Disease; Synaptic Transmission | 2011 |
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Parkinson Disease; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2012 |
Integrating neurotransmission in striatal medium spiny neurons.
Topics: Animals; Cell Nucleus; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Epigenesis, Genetic; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Glutamic Acid; Humans; Motivation; Neuronal Plasticity; Neurons; Parkinson Disease; Receptors, Dopamine D2; Receptors, Glutamate; Synapses; Synaptic Transmission; Thalamus | 2012 |
[Progresses in the study of unbalance of basal ganglia neurotransmitters in Parkinson's disease].
Topics: Acetylcholine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurotransmitter Agents; Parkinson Disease | 2011 |
Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.
Topics: Brain; Dopamine; Dopamine Agents; Glutamic Acid; Humans; Neurons; Neuroprotective Agents; Parkinson Disease | 2013 |
Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle.
Topics: Central Nervous System; Dementia; Evidence-Based Medicine; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Manganese; Parkinson Disease | 2013 |
Amantadine and other antiglutamate agents: management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Glutamic Acid; Humans; Parkinson Disease; Psychomotor Performance; Randomized Controlled Trials as Topic | 2002 |
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Motor Activity; Parkinson Disease; Receptors, Cell Surface | 2002 |
The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article.
Topics: Animals; Corpus Striatum; Dopamine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Neurons; Neuroprotective Agents; Parkinson Disease; Receptors, Metabotropic Glutamate | 2002 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2003 |
[Continuous subthalamic neurostimulation in Parkinson's disease. Indications and modalities].
Topics: Dopamine; Electric Stimulation Therapy; Electrodes, Implanted; Enkephalins; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Parkinson Disease; Patient Selection; Perioperative Care; Referral and Consultation; Risk Factors; Severity of Illness Index; Stereotaxic Techniques; Substance P; Subthalamic Nucleus; Treatment Outcome | 2003 |
Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease.
Topics: Animals; Antioxidants; Astrocytes; Cell- and Tissue-Based Therapy; Cytokines; Excitatory Amino Acids; Glutamic Acid; Humans; Nerve Growth Factors; Parkinson Disease | 2005 |
Cannabinoid control of motor function at the basal ganglia.
Topics: Animals; Basal Ganglia; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Motor Activity; Movement Disorders; Parkinson Disease; Receptor, Cannabinoid, CB1; Signal Transduction | 2005 |
Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Central Nervous System; Clinical Trials, Phase II as Topic; Disease Models, Animal; Glutamic Acid; Humans; Inflammation; Neuroprotective Agents; Parkinson Disease; Purines | 2006 |
New targets for pharmacological intervention in the glutamatergic synapse.
Topics: Alzheimer Disease; Animals; Epilepsy; Glutamic Acid; Humans; Huntington Disease; Ischemia; Parkinson Disease; Protein Kinases; Receptors, N-Methyl-D-Aspartate; Synapses | 2006 |
Cellular principles underlying normal and pathological activity in the subthalamic nucleus.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neural Pathways; Parkinson Disease; Subthalamic Nucleus; Synaptic Transmission | 2006 |
Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies.
Topics: Acetylcholine; Atrophy; Cerebral Cortex; Cholinergic Fibers; Dementia; Glutamic Acid; Humans; Lewy Body Disease; Nerve Degeneration; Parkinson Disease; Receptors, Nicotinic; Serotonin; Synaptic Transmission | 2007 |
Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1995 |
Glutamate and Parkinson's disease.
Topics: Animals; Brain; Glutamates; Glutamic Acid; Humans; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary; Synaptic Transmission | 1994 |
Is selegiline neuroprotective in Parkinson's disease?
Topics: Animals; Brain; Clinical Trials as Topic; Enzyme Induction; Glutamic Acid; Humans; Hydrogen Peroxide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotoxins; Parkinson Disease; Selegiline; Superoxide Dismutase | 1994 |
The role of glutamate in epilepsy and other CNS disorders.
Topics: Animals; Central Nervous System Diseases; Epilepsy; Glutamic Acid; Humans; Lamotrigine; Mice; N-Methylaspartate; Parkinson Disease; Piperazines; Pyrimidines; Rats; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Sodium Channels; Triazines | 1994 |
Recent advances in pharmacological therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Droxidopa; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; NAD; Neurologic Examination; Parkinson Disease; Receptors, Dopamine | 1993 |
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Evaluation, Preclinical; Drug Synergism; Drug Tolerance; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Haplorhini; Humans; Mice; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, Dopamine; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1993 |
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
Topics: Dopamine; Glutamic Acid; Humans; Movement Disorders; Parkinson Disease | 1996 |
Glutamate and Parkinson's disease.
Topics: Animals; Basal Ganglia; Brain; Calcium Channels; Energy Metabolism; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Models, Neurological; Neurons; Neurotoxins; Neurotransmitter Agents; Oxidative Stress; Parkinson Disease; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Synaptic Transmission | 1996 |
Dopamine/glutamate interactions in Parkinson's disease.
Topics: Animals; Basal Ganglia; Dopamine; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Parkinson Disease; Synaptic Transmission | 1997 |
Catecholamines in the central nervous system. Overview.
Topics: Afferent Pathways; Animals; Attention; Behavior, Animal; Brain; Catecholamines; Dopamine; Glutamic Acid; Humans; Memory; Neurons; Neurotransmitter Agents; Parkinson Disease; Receptors, Adrenergic; Receptors, Dopamine; Schizophrenia | 1998 |
Prospects of glutamate antagonists in the therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Basal Ganglia; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Neurotransmitter Agents; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1998 |
Striatal mechanisms in Parkinson's disease: new insights from computer modeling.
Topics: Computer Simulation; Corpus Striatum; Dopamine; Glutamic Acid; Humans; Models, Neurological; Movement; Neural Networks, Computer; Parkinson Disease | 1998 |
Dopamine-glutamate interactions in the basal ganglia.
Topics: Basal Ganglia; Dopamine; Glutamic Acid; Humans; Neuronal Plasticity; Parkinson Disease | 1998 |
Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism.
Topics: Animals; Disease Models, Animal; Dopamine; Glutamic Acid; Mice; Neurons; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1998 |
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Narcotics; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Serotonin | 1999 |
NMDA receptors in the basal ganglia.
Topics: Basal Ganglia; Glutamic Acid; Humans; Huntington Disease; Movement Disorders; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2000 |
Mitochondrial dysfunction in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calcium; Disease Models, Animal; Dopamine; Electron Transport Complex I; Glutamic Acid; Humans; Mitochondria; NADH, NADPH Oxidoreductases; Neurons; Parkinson Disease; Rats; Reactive Oxygen Species | 1999 |
Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease.
Topics: Amino Acid Transport System X-AG; Animals; ATP-Binding Cassette Transporters; Dopamine; Glutamic Acid; Humans; Neurons; Parkinson Disease; Substantia Nigra | 2000 |
Electrophysiology of dopamine in normal and denervated striatal neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons; Parkinson Disease | 2000 |
Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
Topics: Corpus Striatum; Drug Therapy; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Neural Pathways; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2000 |
Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease.
Topics: Basal Ganglia; Brain Chemistry; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurons; Neuropeptides; Parkinson Disease | 2001 |
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Topics: Aging; Alzheimer Disease; Animals; Brain Diseases; Cell Death; Energy Metabolism; Glutamates; Glutamic Acid; Humans; Huntington Disease; Ion Channel Gating; Mitochondria; Models, Biological; MPTP Poisoning; Nerve Degeneration; Neurons; Neurotoxins; Oxidative Phosphorylation; Parkinson Disease; Parkinson Disease, Secondary; Primates; Rats; Receptors, N-Methyl-D-Aspartate | 1992 |
Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia.
Topics: Animals; Brain Chemistry; Dopamine; Glutamates; Glutamic Acid; Humans; Parkinson Disease; Schizophrenia | 1992 |
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.
Topics: Animals; Anticonvulsants; Aspartic Acid; Basal Ganglia; Biogenic Amines; Dibenzocycloheptenes; Dizocilpine Maleate; Glutamates; Glutamic Acid; Humans; N-Methylaspartate; Parkinson Disease; Schizophrenia | 1990 |
Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Basal Ganglia Diseases; Brain; Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Humans; Huntington Disease; Mice; Movement Disorders; Nerve Degeneration; Neurotransmitter Agents; Parkinson Disease; Rats | 1985 |
[Role of catecholamines in regulating motor functions (review)].
Topics: Basal Ganglia; Brain Mapping; Catecholamines; Cerebral Cortex; Cholinergic Fibers; Dopamine; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Hypothalamus; Limbic System; Motor Activity; Neural Pathways; Parkinson Disease; Receptors, Adrenergic; Receptors, Catecholamine; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission; Thalamic Nuclei | 1985 |
6 trial(s) available for glutamic acid and Parkinson Disease
| Article | Year |
|---|---|
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index | 2020 |
Spike-timing-related plasticity is preserved in Parkinson's disease and is enhanced by dopamine: evidence from transcranial magnetic stimulation.
Topics: Acyclovir; Aged; Analysis of Variance; Dopamine; Dopamine Agents; Electric Stimulation; Evoked Potentials, Motor; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Reaction Time; Transcranial Magnetic Stimulation | 2008 |
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Topics: Aged; Aged, 80 and over; Brain; Cognition; Cognition Disorders; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Lewy Body Disease; Male; Memantine; Neuropsychological Tests; Outcome Assessment, Health Care; Parkinson Disease; Patient Selection; Placebo Effect; Placebos; Psychomotor Performance; Reaction Time; Treatment Outcome | 2009 |
Improvement of motor function in early Parkinson disease by safinamide.
Topics: Adult; Aged; Alanine; Antiparkinson Agents; Benzylamines; Calcium Channel Blockers; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Diseases; Glutamic Acid; Humans; Male; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Sodium Channel Blockers; Treatment Outcome | 2004 |
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Riluzole; Treatment Outcome | 2006 |
Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease.
Topics: Aged; Amino Acids; Glutamic Acid; Humans; Parkinson Disease | 1997 |
155 other study(ies) available for glutamic acid and Parkinson Disease
| Article | Year |
|---|---|
Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Topics: Animals; Cells, Cultured; Dendrites; Endosomes; Gain of Function Mutation; Gene Knock-In Techniques; Glutamic Acid; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Miniature Postsynaptic Potentials; Mutation, Missense; Nerve Tissue Proteins; Parkinson Disease; Patch-Clamp Techniques; Point Mutation; Protein Binding; Protein Interaction Mapping; rab GTP-Binding Proteins; Receptors, AMPA; Recombinant Proteins; Synapses; Vesicular Transport Proteins | 2021 |
Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson's disease.
Topics: Animals; Biomechanical Phenomena; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Light; Locomotion; Mice; Mice, Transgenic; Midbrain Reticular Formation; Neurons; Optogenetics; Oxidopamine; Parkinson Disease; Rhodopsin | 2021 |
Induction of Parkinsonian-Like Changes via Targeted Downregulation of Astrocytic Glutamate Transporter GLT-1 in the Striatum.
Topics: Animals; Astrocytes; Down-Regulation; Excitatory Amino Acid Transporter 2; Glutamic Acid; Humans; Parkinson Disease; Positron Emission Tomography Computed Tomography; Rats; Tyrosine 3-Monooxygenase | 2022 |
Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using
Topics: Animals; Glutamic Acid; Glutamine; Humans; Parkinson Disease; Proton Magnetic Resonance Spectroscopy; Putamen | 2022 |
The modulatory effect of 100 Hz electroacupuncture on striatal synaptic plasticity in unilateral lesioned 6-OHDA rats.
Topics: Animals; Corpus Striatum; Electroacupuncture; Glutamic Acid; Humans; Long-Term Potentiation; Oxidopamine; Parkinson Disease; Rats | 2022 |
Visuo-spatial processing is linked to cortical glutamate dynamics in Parkinson's disease - a 7-T functional magnetic resonance spectroscopy study.
Topics: Cognitive Dysfunction; Glutamic Acid; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Parkinson Disease; Spatial Processing | 2023 |
Prevention of Glutamate-Induced Neurodegeneration by Piceatannol via Mitochondrial Rescue In Vitro and In Vivo.
Topics: Animals; Caenorhabditis elegans; Dopaminergic Neurons; Glutamic Acid; Parkinson Disease | 2023 |
In Search of a Feedback Signal for Closed-Loop Deep Brain Stimulation: Stimulation of the Subthalamic Nucleus Reveals Altered Glutamate Dynamics in the Globus Pallidus in Anesthetized, 6-Hydroxydopamine-Treated Rats.
Topics: Animals; Deep Brain Stimulation; Feedback; Globus Pallidus; Glutamic Acid; Oxidopamine; Parkinson Disease; Rats; Subthalamic Nucleus | 2023 |
L-theanine attenuates LPS-induced motor deficit in experimental rat model of Parkinson's disease: emphasis on mitochondrial activity, neuroinflammation, and neurotransmitters.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Lipopolysaccharides; Mitochondria; Neuroinflammatory Diseases; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Rats | 2023 |
Astrocytes Differentiated from LRRK2-I1371V Parkinson's-Disease-Induced Pluripotent Stem Cells Exhibit Similar Yield but Cell-Intrinsic Dysfunction in Glutamate Uptake and Metabolism, ATP Generation, and Nrf2-Mediated Glutathione Machinery.
Topics: Adenosine Triphosphate; Astrocytes; Glutamic Acid; Glutamine; Glutathione; Humans; Induced Pluripotent Stem Cells; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; NF-E2-Related Factor 2; Parkinson Disease | 2023 |
Tannic Acid Mitigates Rotenone-Induced Dopaminergic Neurodegeneration by Inhibiting Inflammation, Oxidative Stress, Apoptosis, and Glutamate Toxicity in Rats.
Topics: Animals; Antioxidants; Apoptosis; Cytokines; Dopaminergic Neurons; Glutamic Acid; Humans; Inflammation; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rotenone | 2023 |
Recovery of motor function is associated with rescue of glutamate biomarkers in the striatum and motor cortex following treatment with Mucuna pruriens in a murine model of Parkinsons disease.
Topics: Animals; Basal Ganglia; Biomarkers; Gait; Glutamic Acid; Mice; Motor Cortex; Mucuna; Parkinson Disease; Pars Compacta; Plant Extracts | 2023 |
Efficacy and mechanism study of Baichanting compound, a combination of Acanthopanax senticosus (Rupr. and Maxim.) Harms, Paeonia lactiflora Pall and Uncaria rhynchophylla (Miq.) Miq. ex Havil, on Parkinson's disease based on metagenomics and metabolomics.
Topics: Animals; Antioxidants; Chromatography, Liquid; Dopamine; Eleutherococcus; Glutamic Acid; Glutamine; Interleukin-6; Malondialdehyde; Metabolomics; Mice; Mice, Inbred C57BL; Paeonia; Parkinson Disease; Superoxide Dismutase; Tandem Mass Spectrometry; Tumor Necrosis Factor-alpha | 2024 |
Wnt1 Promotes EAAT2 Expression and Mediates the Protective Effects of Astrocytes on Dopaminergic Cells in Parkinson's Disease.
Topics: Apoptosis; Astrocytes; beta Catenin; Cell Line; Coculture Techniques; Dopaminergic Neurons; Excitatory Amino Acid Transporter 2; Glutamic Acid; Humans; Oxidopamine; Parkinson Disease; Wnt Signaling Pathway; Wnt1 Protein | 2019 |
Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Glutamic Acid; Male; Microglia; Neuroprotective Agents; Parkinson Disease; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Rats, Sprague-Dawley; Receptor, Macrophage Colony-Stimulating Factor; Swimming; Tropanes | 2020 |
Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis.
Topics: alpha-Synuclein; Animals; Astrocytes; Cell-Derived Microparticles; Disease Progression; Erythrocytes; Glutamic Acid; Homeostasis; Humans; Mice; Parkinson Disease | 2020 |
High γ-Aminobutyric Acid Content Within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients With Parkinson's Disease.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Medically Unexplained Symptoms; Parkinson Disease; Prefrontal Cortex | 2020 |
Accelerated habitual learning resulting from L-dopa exposure in rats is prevented by N-acetylcysteine.
Topics: Acetylcysteine; Animals; Antioxidants; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Dopamine; Dopamine Agents; Glutamic Acid; Habits; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Long-Evans | 2020 |
Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.
Topics: alpha-Synuclein; Animals; Blotting, Western; Corpus Striatum; Dopamine; Excitatory Postsynaptic Potentials; Gene Knockout Techniques; Glutamic Acid; Immunohistochemistry; Microscopy, Electron; Mitochondria; Neostriatum; Neurons; Parkinson Disease; Patch-Clamp Techniques; Protein Kinases; Rats; Synaptic Transmission | 2021 |
Cytokinin Plant Hormones Have Neuroprotective Activity in In Vitro Models of Parkinson's Disease.
Topics: Acetylcysteine; Caspase 3; Caspase 7; Cell Death; Cell Differentiation; Cell Line, Tumor; Cytokinins; Glutamic Acid; Humans; Isoquinolines; Models, Biological; Neurons; Neuroprotective Agents; Oxidative Stress; Oxygen; Parkinson Disease; Plant Growth Regulators; Superoxides | 2021 |
Revisiting dopamine-acetylcholine imbalance in Parkinson's disease: Glutamate co-transmission as an exciting partner in crime.
Topics: Acetylcholine; Animals; Cholinergic Agents; Corpus Striatum; Crime; Dopamine; Glutamic Acid; Interneurons; Mice; Motor Disorders; Parkinson Disease | 2021 |
A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues.
Topics: alpha-Synuclein; Amino Acid Substitution; beta-Synuclein; Glutamic Acid; Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Microfibrils; Models, Molecular; Mutagenesis, Site-Directed; Parkinson Disease; Peptide Fragments; Point Mutation; Protein Aggregation, Pathological; Protein Interaction Domains and Motifs; Recombinant Fusion Proteins | 2017 |
Neuroprotective effects of a Coeloglossum viride var. Bracteatum extract in vitro and in vivo.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; Fluorescent Antibody Technique; Glutamic Acid; Immunohistochemistry; Mice; Neurons; Neuroprotective Agents; Orchidaceae; Oxidative Stress; Parkinson Disease; Phosphatidylinositol 3-Kinases; Plant Extracts; Protein Kinase C; Proto-Oncogene Proteins c-akt; Rats | 2017 |
Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Female; Glutamic Acid; Humans; Male; Mesencephalon; Mice; Neurodegenerative Diseases; Neurons; Neurotoxins; Parkinson Disease; Substantia Nigra; Transgenes; Ventral Tegmental Area; Vesicular Glutamate Transport Protein 2 | 2018 |
Rehabilitation program based on sensorimotor recovery improves the static and dynamic balance and modifies the basal ganglia neurochemistry: A pilot 1H-MRS study on Parkinson's disease patients.
Topics: Aged; Basal Ganglia; Female; Glutamic Acid; Glutamine; Humans; Male; Parkinson Disease; Pilot Projects; Postural Balance | 2017 |
In vivo GluCEST MRI: Reproducibility, background contribution and source of glutamate changes in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Transport; Disease Models, Animal; Glutamic Acid; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neostriatum; Neuroglia; Parkinson Disease; Reproducibility of Results | 2018 |
Neurotransmitter activity is linked to outcome following subthalamic deep brain stimulation in Parkinson's disease.
Topics: Aged; Basal Ganglia; Deep Brain Stimulation; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Pons; Subthalamic Nucleus | 2018 |
Glial loss of the metallo β-lactamase domain containing protein, SWIP-10, induces age- and glutamate-signaling dependent, dopamine neuron degeneration.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dopaminergic Neurons; Glutamic Acid; Humans; Nerve Tissue Proteins; Neuroglia; Parkinson Disease; Signal Transduction | 2018 |
Blockade of Rapid Influx of Extracellular Zn
Topics: Animals; Behavior, Animal; Chelating Agents; Dopaminergic Neurons; Extracellular Space; Glutamic Acid; Male; Models, Biological; Movement Disorders; Nerve Degeneration; Paraquat; Parkinson Disease; Rats, Wistar; Reactive Oxygen Species; Substantia Nigra; Zinc | 2019 |
Cholinergic Interneurons Amplify Thalamostriatal Excitation of Striatal Indirect Pathway Neurons in Parkinson's Disease Models.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Excitatory Postsynaptic Potentials; Glutamic Acid; Interneurons; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Receptors, Nicotinic; Thalamus | 2019 |
A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced Excitotoxicity.
Topics: Computer Simulation; Dopaminergic Neurons; Excitatory Amino Acid Agonists; Glutamic Acid; Humans; Models, Neurological; Parkinson Disease | 2019 |
Effects of exercise on mGluR-mediated glutamatergic transmission in the striatum of hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Exercise Therapy; Glutamic Acid; Locomotion; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2019 |
Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.
Topics: Acetylcholine; Animals; Brain; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Gene Knockout Techniques; Glutamic Acid; Glycine; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Parkinson Disease; Protein Deglycase DJ-1; Protein Kinases; Rats; Serotonin; Ubiquitin-Protein Ligases | 2019 |
Paraquat as an Environmental Risk Factor in Parkinson's Disease Accelerates Age-Related Degeneration Via Rapid Influx of Extracellular Zn
Topics: Aging; Animals; Dopaminergic Neurons; Exocytosis; Extracellular Space; Glutamic Acid; Male; Paraquat; Parkinson Disease; Presynaptic Terminals; Rats, Wistar; Reactive Oxygen Species; Receptors, AMPA; Risk Factors; Substantia Nigra; Zinc | 2019 |
Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels.
Topics: Animals; Antioxidants; Catalepsy; Corpus Striatum; Deferoxamine; Dextromethorphan; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug Combinations; Drug Synergism; Glutamic Acid; Hydroxydopamines; Male; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Wistar | 2019 |
Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson's Disease.
Topics: Animals; Caspase 3; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Enzyme Activation; Genotype; Glutamic Acid; Long-Term Synaptic Depression; Mice; Mice, Knockout; Neuronal Plasticity; Parkinson Disease; Protein Kinases | 2019 |
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.
Topics: Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dopaminergic Neurons; Enzyme Inhibitors; Glutamic Acid; Glycogen Synthase Kinase 3; Humans; Mice; Microglia; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Male; Motor Activity; Neostriatum; Parkinson Disease; Progesterone; Rats; Rats, Sprague-Dawley | 2013 |
Striatal glutamate induces retrograde excitotoxicity and neuronal degeneration of intralaminar thalamic nuclei: their potential relevance for Parkinson's disease.
Topics: Action Potentials; Animals; Cell Death; Corpus Striatum; Dopamine; Dopamine Agents; Glutamic Acid; Intralaminar Thalamic Nuclei; Levodopa; Male; Microglia; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Synapses; Synaptic Transmission; Vesicular Glutamate Transport Protein 2 | 2013 |
NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
Topics: Animals; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tryptophan | 2014 |
Astrocytic dynamin-like protein 1 regulates neuronal protection against excitotoxicity in Parkinson disease.
Topics: Astrocytes; Calcium; Calcium Signaling; Cell Survival; Dynamins; Female; Gene Knockdown Techniques; Glutamic Acid; GTP Phosphohydrolases; Humans; Male; Microtubule-Associated Proteins; Mitochondria; Mitochondrial Proteins; Neurons; Parkinson Disease | 2015 |
Glutamate and GABA concentration changes in the globus pallidus internus of Parkinson's patients during performance of implicit and declarative memory tasks: a report of two subjects.
Topics: Acoustic Stimulation; Deep Brain Stimulation; Female; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Humans; Memory; Microdialysis; Parkinson Disease; Photic Stimulation; Speech Perception; Subthalamic Nucleus; Visual Perception | 2015 |
A tripeptide isolated from Bothrops atrox venom has neuroprotective and neurotrophic effects on a cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Bothrops; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dopamine; Dopaminergic Neurons; Glutamic Acid; Mitochondria; Models, Biological; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Peptides; Rats; Tryptophan; Valine; Venoms | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
Ziram, a pesticide associated with increased risk for Parkinson's disease, differentially affects the presynaptic function of aminergic and glutamatergic nerve terminals at the Drosophila neuromuscular junction.
Topics: Animals; Dopamine; Drosophila melanogaster; Endocytosis; Exocytosis; Fungicides, Industrial; Glutamic Acid; Neuromuscular Junction; Parkinson Disease; Presynaptic Terminals; Ziram | 2016 |
Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Corpus Striatum; Deep Brain Stimulation; Dopamine; Glutamic Acid; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Subthalamic Nucleus; Time | 2016 |
[Effect of Electroacupuncture Intervention on Expression of Cx 43 and Concentration of Glutamate in the Striatum of Rats with Parkinson's Disease].
Topics: Acupuncture Points; Animals; Connexin 43; Corpus Striatum; Electroacupuncture; Glutamic Acid; Humans; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2015 |
Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.
Topics: Animals; Astrocytes; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Gliosis; Glutamate Decarboxylase; Glutamic Acid; Glutathione; Lactic Acid; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Vasoactive Intestinal Peptide | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Catalepsy; Disease Models, Animal; Dopamine Agonists; Forelimb; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Transfection | 2016 |
Neuroprotection comparison of chlorogenic acid and its metabolites against mechanistically distinct cell death-inducing agents in cultured cerebellar granule neurons.
Topics: Animals; Antioxidants; Apoptosis; Caffeic Acids; Cell Death; Chlorogenic Acid; Coffee; Coumaric Acids; Cytoplasmic Granules; Glutamic Acid; Gray Matter; Hydrogen Peroxide; Neurons; Neuroprotection; Neuroprotective Agents; Nitroprusside; Parkinson Disease; Primary Cell Culture; Rats; Rats, Sprague-Dawley | 2016 |
Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Dopamine; Dopaminergic Neurons; GABAergic Neurons; gamma-Aminobutyric Acid; Gastrin-Releasing Peptide; Gene Expression Regulation; Glutamic Acid; Humans; Mice; Mice, Transgenic; Nerve Tissue Proteins; Optogenetics; Parkinson Disease; Pars Compacta; Synaptic Transmission; TRPV Cation Channels; Ventral Tegmental Area | 2016 |
Blunted mGluR Activation Disinhibits Striatopallidal Transmission in Parkinsonian Mice.
Topics: Animals; Astrocytes; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Mice, Inbred C57BL; Neurons; Parkinson Disease; Receptors, Metabotropic Glutamate; Signal Transduction; Synaptic Transmission | 2016 |
VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Aβ accumulation via enhancement of ERK phosphatase VHR activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Cell Line, Tumor; Cell Nucleus; Dual Specificity Phosphatase 3; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glutamic Acid; HSP70 Heat-Shock Proteins; Humans; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Protein Binding; Protein Serine-Threonine Kinases; Protein Transport | 2016 |
Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein.
Topics: alpha-Synuclein; Animals; Glutamic Acid; Humans; Mice; Parkinson Disease; Synaptosomes | 2017 |
Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amino Acid Transport System X-AG; Animals; Astrocytes; Cells, Cultured; Corpus Striatum; Cytoplasm; Disease Models, Animal; Endosomal Sorting Complexes Required for Transport; Glutamic Acid; Male; Membranes; Mesencephalon; Mice; Mice, Inbred C57BL; Nedd4 Ubiquitin Protein Ligases; Parkinson Disease; Protein Kinase C; Protein Serine-Threonine Kinases; Protein Transport; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases; Ubiquitination | 2017 |
GABAergic mechanism mediated via D receptors in the rat periaqueductal gray participates in the micturition reflex: an in vivo microdialysis study.
Topics: Animals; Benzazepines; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Extracellular Space; gamma-Aminobutyric Acid; Glutamic Acid; Male; Microdialysis; Oxidopamine; Parkinson Disease; Periaqueductal Gray; Rats; Rats, Wistar; Receptors, Dopamine D1; Reflex; Sympatholytics; Urination | 2008 |
Cysteine pKa depression by a protonated glutamic acid in human DJ-1.
Topics: Crystallization; Cysteine; Databases, Genetic; Glutamic Acid; Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Intracellular Signaling Peptides and Proteins; Models, Molecular; Oncogene Proteins; Oxidative Stress; Parkinson Disease; Protein Conformation; Protein Deglycase DJ-1; Recombinant Proteins; X-Ray Diffraction | 2008 |
Compensatory mechanisms in Parkinson's disease.
Topics: Basal Ganglia; Dopamine; Dopamine Agonists; Glutamic Acid; Humans; Parkinson Disease | 2009 |
Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.
Topics: Alpha Rhythm; Animals; Apomorphine; Behavior, Animal; Beta Rhythm; Cerebral Cortex; Corpus Striatum; Delta Rhythm; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Drug Interactions; Electroencephalography; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Osmotic Fragility; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics; Theta Rhythm | 2008 |
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studies; Choline; Creatine; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic Resonance Spectroscopy; Male; Mental Status Schedule; Middle Aged; Nootropic Agents; Parkinson Disease | 2008 |
Pruning and loss of excitatory synapses by the parkin ubiquitin ligase.
Topics: Animals; Cells, Cultured; Cerebral Cortex; Excitatory Postsynaptic Potentials; Glutamic Acid; Hippocampus; Mutation; Neurons; Neurotoxins; Parkinson Disease; Patch-Clamp Techniques; Rats; Synapses; Synaptic Transmission; Ubiquitin-Protein Ligases | 2008 |
Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1.
Topics: Amino Acid Substitution; Animals; Cell Line, Tumor; Cysteine; Genetic Diseases, Inborn; Glutamic Acid; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mitochondrial Proteins; Mutation; Oncogene Proteins; Oxidation-Reduction; Parkinson Disease; Protein Deglycase DJ-1; Sulfinic Acids | 2009 |
Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum.
Topics: Animals; Corpus Striatum; Dopamine; Down-Regulation; Electric Stimulation; Glutamic Acid; Male; Neural Inhibition; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission; Up-Regulation | 2009 |
Memantine: a new hope for treatment of Lewy body-related dementias?
Topics: Aged; Brain; Brain Chemistry; Clinical Trials as Topic; Drug Interactions; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Lewy Body Disease; Memantine; Parkinson Disease; Placebo Effect; Synaptic Transmission; Treatment Outcome | 2009 |
The specificity of neuroprotection by antioxidants.
Topics: Alzheimer Disease; Animals; Antioxidants; Cell Survival; Fluorescent Dyes; Glutamic Acid; Membrane Potentials; Mice; Microscopy, Fluorescence; Mitochondria; Neuroprotective Agents; Oxygen; Parkinson Disease; Phosphorylation; Reactive Oxygen Species | 2009 |
Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.
Topics: Alanine; alpha-Synuclein; Genetic Variation; Glutamic Acid; Humans; Lysine; Magnetic Resonance Spectroscopy; Mutagenesis, Site-Directed; Parkinson Disease; Peptide Fragments; Phospholipids; Proline; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Solutions; Threonine | 2010 |
SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination.
Topics: Acyltransferases; Amino Acid Sequence; Animals; Cell Line; Glutamic Acid; Humans; Mice; Models, Molecular; Molecular Sequence Data; Parkinson Disease; Protein Binding; Protein Isoforms; Protein Structure, Tertiary; Recombinant Fusion Proteins; Sequence Alignment; src Homology Domains; Synapses; Synaptic Transmission; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination | 2009 |
Striatal spine plasticity in Parkinson's disease: pathological or not?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Diagnosis, Computer-Assisted; Glutamic Acid; Humans; Neural Pathways; Neuronal Plasticity; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Synaptic Transmission | 2009 |
alpha-Synuclein at the synaptic gate.
Topics: alpha-Synuclein; Dopamine; Gene Duplication; Glutamic Acid; Humans; Parkinson Disease; Synapses; Synaptic Transmission | 2010 |
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Aspartic Acid; Disease Models, Animal; Excitatory Amino Acid Agonists; Glutamic Acid; Immunohistochemistry; Male; Microdialysis; Motor Activity; Neuroprotective Agents; Parkinson Disease; Phosphoserine; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Substantia Nigra | 2010 |
Neuroscience: Brain's traffic lights.
Topics: Animals; Behavior, Animal; Dopamine; Glutamic Acid; Humans; Learning; Mice; Models, Neurological; Neostriatum; Neural Pathways; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2010 |
[Effect of stimulation of STN on the firing activities of the SNr neurons in rats].
Topics: Action Potentials; Animals; Electric Stimulation; Electrophoresis; gamma-Aminobutyric Acid; Glutamic Acid; Male; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus | 2009 |
Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease.
Topics: Aged; Brain; Choline; Corpus Striatum; Creatine; Diffusion Tensor Imaging; Dipeptides; Female; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Parkinson Disease; Severity of Illness Index; Substantia Nigra | 2011 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Glutamic Acid; Lipopolysaccharides; Male; Mice; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Reserpine; Substantia Nigra | 2012 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Glutamic Acid; Immunohistochemistry; L-Lactate Dehydrogenase; Male; Matrix Metalloproteinase 9; Nerve Degeneration; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Simvastatin; Substantia Nigra; Tritium; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
A liquid phase based C. elegans behavioral analysis system identifies motor activity loss in a nematode Parkinson's disease model.
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Electronic Data Processing; Glutamic Acid; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Motor Activity; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Serine; Software | 2012 |
Pathophysiology of freezing of gait and some possible treatments for it.
Topics: Amines; Cyclohexanecarboxylic Acids; Dopamine; Excitatory Amino Acid Antagonists; Gabapentin; Gait; Gait Disorders, Neurologic; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Models, Theoretical; Neural Networks, Computer; Parkinson Disease | 2012 |
Glutamate-based depression GBD.
Topics: Affect; Alzheimer Disease; Arthritis, Rheumatoid; Chronic Pain; Cognition; Coronary Artery Disease; Depression; Diabetes Complications; Fibromyalgia; Glutamic Acid; Gyrus Cinguli; Humans; Huntington Disease; Inflammation; Interferons; Models, Neurological; Models, Psychological; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Risk Factors; Stroke; Synaptic Transmission | 2012 |
Inhibition of glutamate and acetylcholine release in behavioral improvement induced by electroacupuncture in parkinsonian rats.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Electroacupuncture; gamma-Aminobutyric Acid; Glutamic Acid; Male; Motor Activity; Neurons; Parkinson Disease; Rats; Rats, Wistar; Stereotyped Behavior | 2012 |
Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Magnetic Resonance Spectroscopy; Male; Multivariate Analysis; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2013 |
Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.
Topics: Animals; Basal Ganglia; Cognition; Dopamine Agonists; Dopaminergic Neurons; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Learning; Levodopa; Memory; Models, Neurological; Parkinson Disease; Prefrontal Cortex; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2013 |
Somatic transposition in the brain has the potential to influence the biosynthesis of metabolites involved in Parkinson's disease and schizophrenia.
Topics: Brain; Computational Biology; DNA Transposable Elements; Dopamine; Glutamic Acid; Humans; Neurotransmitter Agents; Organ Specificity; Parkinson Disease; Schizophrenia; Serotonin | 2012 |
Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Corpus Striatum; Dopamine; Dopaminergic Neurons; Glutamic Acid; Hydroxyl Radical; Inflammation; Lipopolysaccharides; Male; Microinjections; Parkinson Disease; Purines; Rats; Receptor, Adenosine A2A | 2013 |
The multiple actions of selegiline.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Dopamine; Female; Glutamic Acid; Mesencephalon; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Selegiline | 2002 |
Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
Topics: Animals; Dendrites; Dopamine; Dopamine Antagonists; Drug Synergism; Extracellular Space; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Haloperidol; Male; Microdialysis; Muscimol; Neural Inhibition; Neural Pathways; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Substantia Nigra; Subthalamic Nucleus; Synaptic Transmission | 2003 |
The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Aspartic Acid; Basal Ganglia; Chromatography, High Pressure Liquid; Excitatory Amino Acid Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Immunohistochemistry; Injections, Intraventricular; Kainic Acid; Male; Microdialysis; Models, Animal; Oxidopamine; Parkinson Disease; Potassium; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2003 |
The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Chi-Square Distribution; Cohort Studies; DNA Mutational Analysis; Female; Gene Frequency; Glutamic Acid; Glycine; Humans; Male; Membrane Proteins; Middle Aged; Parkinson Disease; Point Mutation; Poland; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Presenilin-1 | 2004 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
[Relationship between neurotoxicity of 6-hydroxydopamine and glutamate transport].
Topics: Amino Acid Transport System X-AG; Animals; Apoptosis; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley | 2003 |
Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients.
Topics: Adenosine Diphosphate; Adult; Aged; Amobarbital; Antioxidants; Cells, Cultured; Coenzymes; Drug Interactions; Female; Fibroblasts; Glutamic Acid; Humans; Male; Middle Aged; Mitochondria; NAD; Oxygen; Parkinson Disease; Pyruvic Acid; Skin; Ubiquinone | 2004 |
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Models, Animal; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Synaptic Transmission | 2004 |
Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Drug Administration Schedule; Excitatory Amino Acid Transporter 2; Extracellular Fluid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar | 2004 |
Effects of glutamate and MK-801 on the metabolism of dopamine in the striatum of normal and parkinsonian rats.
Topics: Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Female; Glutamic Acid; Microdialysis; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2005 |
Developmental pesticide exposures and the Parkinson's disease phenotype.
Topics: Age Factors; Animals; Disease Models, Animal; Dopamine; Female; Glutamic Acid; Humans; Mice; Parkinson Disease; Pesticides; Pregnancy; Prenatal Exposure Delayed Effects | 2005 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Disease Models, Animal; Glutamic Acid; Injections, Subcutaneous; Male; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Receptor Agonists; Sympatholytics | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement Disorders; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission | 2005 |
Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn; Brain; Cell Death; Cell Nucleus; Cerebral Cortex; Corpus Striatum; Dopamine; Drug Synergism; Glutamic Acid; N-Methylaspartate; Nerve Degeneration; Neurons; Neurotoxins; Organ Culture Techniques; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
ATP-sensitive potassium channel opener iptakalim protected against the cytotoxicity of MPP+ on SH-SY5Y cells by decreasing extracellular glutamate level.
Topics: 1-Methyl-4-phenylpyridinium; Amino Acid Transport System X-AG; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cytoprotection; Down-Regulation; Extracellular Fluid; Glutamic Acid; Humans; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Propylamines; Receptors, Drug; RNA, Messenger; Sulfonylurea Receptors | 2005 |
Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations.
Topics: Aspartic Acid; Feasibility Studies; gamma-Aminobutyric Acid; Glutamic Acid; Glutathione; Humans; Magnetic Resonance Spectroscopy; Parkinson Disease; Protons; Substantia Nigra | 2006 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; gamma-Aminobutyric Acid; Gene Expression; Glutamic Acid; In Situ Hybridization; Injections, Intraventricular; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Superoxide Dismutase-1; Tyrosine 3-Monooxygenase | 2006 |
Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Agonists; GABA Antagonists; Glutamic Acid; In Vitro Techniques; Isonicotinic Acids; Neural Pathways; Neurons; Parkinson Disease; Patch-Clamp Techniques; Picrotoxin; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Synaptic Transmission; Time Factors | 2006 |
Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Survival; Cells, Cultured; Dopamine; Dose-Response Relationship, Drug; Glutamic Acid; Immunohistochemistry; Mesencephalon; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Rats | 2007 |
Substantia nigra osmoregulation: taurine and ATP involvement.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adenosine Triphosphate; Animals; Choline; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Hypertonic Solutions; Hypotonic Solutions; Male; Microdialysis; Parkinson Disease; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Purinergic P2; Substantia Nigra; Taurine; Time Factors; Water-Electrolyte Balance | 2007 |
Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease.
Topics: Adult; DNA Mutational Analysis; Female; Glutamic Acid; Humans; Italy; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Serine | 2007 |
Metabotropic glutamate receptors.
Topics: Animals; Antipsychotic Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ligands; Models, Biological; Neurotransmitter Agents; Parkinson Disease; Psychotic Disorders; Receptors, Metabotropic Glutamate | 2007 |
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Glutamic Acid; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin Receptor Agonists | 2007 |
Stimulation-induced dyskinesias inform basal ganglia models and the mechanisms of deep brain stimulation.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Dyskinesias; Glutamic Acid; Humans; Models, Neurological; Parkinson Disease; Substantia Nigra | 2007 |
Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; DNA Mutational Analysis; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glutamic Acid; Humans; Lysine; Male; Middle Aged; Norway; Parkinson Disease; Polymorphism, Genetic; Protein Serine-Threonine Kinases | 2007 |
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Topics: Antiparkinson Agents; Aspartic Acid; Corpus Striatum; Creatine; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Levodopa; Magnetic Resonance Spectroscopy; Parkinson Disease; Reference Values | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Neural Inhibition; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Substantia Nigra; Synaptic Transmission | 2007 |
Reduced brain glutamate in patients with Parkinson's disease.
Topics: Aged; Brain; Demography; Female; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic Resonance Spectroscopy; Male; Parkinson Disease | 2008 |
Nitrated alpha-synuclein and microglial neuroregulatory activities.
Topics: alpha-Synuclein; Animals; Cathepsin B; Cells, Cultured; Cystatins; Cysteine; Cytoskeletal Proteins; Dopamine; Gene Expression Regulation; Glutamic Acid; Glutathione; Mice; Mice, Inbred C57BL; Microglia; Nerve Tissue Proteins; NF-kappa B; Nitrates; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Protein Array Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2008 |
Excitatory amino acid receptors.
Topics: Animals; Aspartic Acid; Binding Sites; Brain; Glutamates; Glutamic Acid; Humans; Kainic Acid; Kinetics; Neurons; Parkinson Disease; Protein Conformation; Receptors, Cell Surface; Receptors, Glutamate; Receptors, Neurotransmitter; Spinal Cord | 1981 |
Oral glutamate loading in disorders with spinocerebellar and extrapyramidal involvement: effect on plasma glutamate, aspartate and taurine.
Topics: Aspartic Acid; Atrophy; Basal Ganglia Diseases; Cerebellar Diseases; Cerebellum; Friedreich Ataxia; Glutamate Dehydrogenase; Glutamates; Glutamic Acid; Humans; Nerve Degeneration; Olivary Nucleus; Parkinson Disease; Pons; Shy-Drager Syndrome; Sodium Glutamate; Spinal Cord Diseases; Taurine | 1983 |
[Functional and pathophysiological aspects of the basal ganglia].
Topics: Adolescent; Basal Ganglia; Child; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Motor Activity; Neurons; Parkinson Disease; Synaptic Transmission | 1984 |
[GABA, glutamate, aspartate, glycine, and taurine contents in spinocerebellar degeneration and parkinsonism].
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Brain Chemistry; Cerebellar Ataxia; Chromatography, High Pressure Liquid; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Male; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Taurine | 1984 |
Neuroprotective mechanism of bromocriptine.
Topics: Amino Acid Transport System X-AG; Antiparkinson Agents; ATP-Binding Cassette Transporters; Biological Transport; Bromocriptine; Carrier Proteins; Dopamine Agonists; Glutamic Acid; HeLa Cells; Humans; Neuroprotective Agents; Parkinson Disease | 1995 |
Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Basal Ganglia; Cycloleucine; Electromyography; Glutamates; Glutamic Acid; Kainic Acid; Male; Muscles; N-Methylaspartate; Parkinson Disease; Rats; Receptors, Glutamate | 1993 |
Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Autoradiography; Binding Sites; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Glutamic Acid; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; N-Methylaspartate; Nerve Tissue Proteins; Parkinson Disease; Receptors, Amino Acid; Receptors, AMPA; Receptors, Glutamate | 1994 |
Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesis.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Glutamates; Glutamic Acid; Humans; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Rats; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1993 |
An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.
Topics: Animals; Brain Chemistry; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamates; Glutamic Acid; Parkinson Disease | 1993 |
Lamotrigine--antiparkinsonian activity by blockade of glutamate release?
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Female; Glutamates; Glutamic Acid; Humans; Lamotrigine; Male; Middle Aged; Parkinson Disease; Triazines | 1993 |
Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Dizocilpine Maleate; Dopamine; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Mesencephalon; NAD(P)H Dehydrogenase (Quinone); Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 1996 |
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
Topics: Aged; Amino Acids; Asparagine; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Glycine; Humans; Male; Middle Aged; Neurotransmitter Agents; Parkinson Disease | 1996 |
Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
Topics: Aged; Apomorphine; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Parkinson Disease | 1997 |
Gene therapy for the nervous system.
Topics: Animals; Cell Death; Cerebrovascular Disorders; Dopamine; Genetic Therapy; Genetic Vectors; Glutamic Acid; Humans; Nervous System Diseases; Neurons; Neurotransmitter Agents; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Viruses | 1997 |
Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Kynurenic Acid; Macaca; Parkinson Disease; Substantia Nigra | 1997 |
Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death.
Topics: Animals; Cells, Cultured; Corticosterone; Dopamine; Estradiol; Estrogen Antagonists; Glutamic Acid; Hydrogen Peroxide; Mesencephalon; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Reactive Oxygen Species; Stereoisomerism; Superoxides; Tamoxifen; Testosterone | 1998 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextrorphan; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate | 1998 |
Immunohistochemical localization of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat.
Topics: Animals; Antibodies; Basal Ganglia; Dopamine; Fluorescent Antibody Technique; Glutamic Acid; Male; Microscopy, Confocal; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1999 |
Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Design; Gene Expression Regulation; Glutamic Acid; In Situ Hybridization; Male; Motor Activity; Neocortex; Nerve Tissue Proteins; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Metabotropic Glutamate; RNA, Messenger; Schizophrenia; Stereotyped Behavior; Sympatholytics; Tegmentum Mesencephali | 1999 |
A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
Topics: Aged; Aspartic Acid; Cerebral Cortex; Choline; Corpus Striatum; Creatine; Female; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Movement Disorders; Parietal Lobe; Parkinson Disease; Reference Values; Temporal Lobe | 1999 |
Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Cysteine; Glutamic Acid; Glutathione; Glycine; Hydrolysis; Hydroxyl Radical; Iron; Kinetics; Male; Microdialysis; Mitochondria; Models, Chemical; Nitro Compounds; Oxygen Consumption; Parkinson Disease; Perfusion; Propionates; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1999 |
Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata.
Topics: Animals; Bridged Bicyclo Compounds; Catalepsy; Dopamine Antagonists; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Glutamic Acid; Haloperidol; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Receptors, Presynaptic; Substantia Nigra; Subthalamic Nucleus | 2000 |
L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Arginine; Citrulline; Glutamic Acid; Humans; Middle Aged; Multiple System Atrophy; Neurons; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease | 2000 |
Reduced platelet glutamate uptake in Parkinson's disease.
Topics: Analysis of Variance; Blood Platelets; Case-Control Studies; Energy Metabolism; Female; Glutamic Acid; Humans; Male; Parkinson Disease | 1999 |
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro.
Topics: Acetaminophen; Animals; Aspirin; Cell Count; Cells, Cultured; Dopamine; Fetus; Glutamic Acid; Ibuprofen; Mesencephalon; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Rats | 2000 |
Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pilot Projects; Reference Values | 2000 |
A light and electron microscopic study of glutamate receptors in the monkey subthalamic nucleus.
Topics: Animals; Female; Glutamic Acid; Immunohistochemistry; Macaca fascicularis; Male; Microscopy, Electron; Neurons; Parkinson Disease; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus | 2000 |
Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease.
Topics: alpha-Synuclein; Apolipoproteins E; Blood Platelets; Brain; Cell Death; Energy Metabolism; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genotype; Glutamic Acid; Humans; Mitochondria; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Polymorphism, Genetic; Risk Factors; Synucleins | 2001 |
Dendrodendritic inhibition through reversal of dopamine transport.
Topics: Animals; Biological Transport; Calcium; Carrier Proteins; Dendrites; Dopamine; Dopamine D2 Receptor Antagonists; Dopamine Plasma Membrane Transport Proteins; Electric Stimulation; Electrophysiology; Evoked Potentials; Excitatory Postsynaptic Potentials; Exocytosis; Glutamic Acid; Humans; In Vitro Techniques; Membrane Glycoproteins; Membrane Potentials; Membrane Transport Proteins; Nerve Tissue Proteins; Neural Inhibition; Neurons; Parkinson Disease; Patch-Clamp Techniques; Piperazines; Rats; Receptors, Dopamine D2; Sodium; Substantia Nigra; Subthalamic Nucleus | 2001 |
Dopamine and glutamate induce distinct striatal splice forms of Ania-6, an RNA polymerase II-associated cyclin.
Topics: Alternative Splicing; Amino Acid Sequence; Animals; Cocaine; Corpus Striatum; COS Cells; Cyclin-Dependent Kinases; Cyclins; Dopamine; Gene Expression Regulation; Genes, Immediate-Early; Glutamic Acid; Male; Mice; Molecular Sequence Data; Parkinson Disease; PC12 Cells; Phosphorylation; Rats; Rats, Sprague-Dawley; RNA Polymerase II; Transfection | 2001 |
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Topics: Anticonvulsants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Riluzole | 2001 |
Glutamate receptors in the substantia nigra of Parkinson's disease brains.
Topics: Aged; Glutamates; Glutamic Acid; Humans; Parkinson Disease; Radioligand Assay; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Substantia Nigra | 1992 |
[Glutamic acid antagonists as antiparkinson agents?].
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Glutamic Acid; Parkinson Disease | 1992 |
Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy.
Topics: Age Factors; Aged; Aged, 80 and over; Dementia; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Luminescent Measurements; Male; Middle Aged; Neuropsychological Tests; Olivopontocerebellar Atrophies; Parkinson Disease | 1992 |
Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Female; Glutamates; Glutamic Acid; Glycine; Humans; Male; Middle Aged; Parkinson Disease | 1992 |
Tetrahydrobiopterin and dopamine release.
Topics: Animals; Biopterins; Brain; Brain Mapping; Dopamine; Glutamates; Glutamic Acid; Haplorhini; Humans; Parkinson Disease; Rats; Receptors, Dopamine; Second Messenger Systems; Serotonin; Synaptic Transmission | 1991 |
Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain.
Topics: Adenosine Triphosphate; Animals; Brain; Glutamates; Glutamic Acid; Humans; Isoquinolines; Malates; Male; Mice; Mice, Inbred C57BL; Mitochondria; NAD(P)H Dehydrogenase (Quinone); Oxygen Consumption; Parkinson Disease; Pyruvates; Pyruvic Acid; Quinone Reductases; Tetrahydroisoquinolines; Tetrahydropapaveroline | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Fluphenazine; Glutamates; Glutamic Acid; Male; Microinjections; Parkinson Disease; Phencyclidine; Rats; Receptors, Glutamate; Receptors, Neurotransmitter; Sulpiride | 1990 |
Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease.
Topics: Animals; Basal Ganglia; Glutamates; Glutamic Acid; Humans; Neurotransmitter Agents; Parkinson Disease | 1989 |
Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Topics: Brain Chemistry; Corpus Striatum; Dopamine; Ethanolamines; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamates; Glutamic Acid; Humans; Parkinson Disease | 1986 |
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Ethanolamine; Ethanolamines; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Glycine; Humans; Male; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Proline; Tremor | 1987 |